InvestorsHub Logo
icon url

BLey

07/27/20 5:12 PM

#98855 RE: dloggold #98853

It’s a 2/3 trial. We don’t need a stand alone phase 3 trial. Our drug is already safe. It just needs to meet end points. ( at least this is my understanding )
icon url

justdafactss

07/27/20 5:16 PM

#98857 RE: dloggold #98853

Looks like CYDY has absolutely NOTHING

NP hyping safety instead of efficacy results is very telling.

Shareholders seem to be taken for a ride.
icon url

Whosonfirst

07/27/20 5:36 PM

#98868 RE: dloggold #98853

Hgen Remsavier When one drug can’t get significant efficiency by itself than it makes sense to try it as a cocktail. Sometimes the side effects are worse from combining 2 drugs, or they might not show any improvement in efficiency. Leronlimab is furthest along imo of any Covid drug and it’s Safety data profile is untouchable to any other treatment. If this were a football game it would be Leronlimab 62 Competition 24 in the 4th quarter.
icon url

bluefish1

07/27/20 5:56 PM

#98879 RE: dloggold #98853

The Covid Phase 2b/3 trial for severe and critical patients is a registrational trial. Look it up if you don't know what it is. Do your own due diligence, and don't take anyone's word here.

It is

a basis for initial Regulatory Approval of such Product.



There is also a phase 2 trial with the data unblinded and being analyzed. Two separate things.